← Back to Search

Corticosteroid

Intralesional Triamcinolone 40 mg/mL for Hidradenitis Suppurativa

Phase 4
Waitlist Available
Led By Steven R Cohen, MD, MPH
Research Sponsored by Montefiore Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up days 2, 6, 14, and 28
Awards & highlights

Study Summary

This trial will test whether higher doses of triamcinolone can more effectively treat HS flares, as well as whether there is a difference in side effects between the doses.

Eligible Conditions
  • Hidradenitis Suppurativa

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, days 2, 6, 14, and 28
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, days 2, 6, 14, and 28 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change From Baseline in Numeric Rating Scale (NRS)
Secondary outcome measures
Baseline Patient Satisfaction Likert Scale
Change From Baseline in C-reactive Protein (CRP)
Change From Baseline in Erythrocyte Sedimentation Rate (ESR)
+6 more

Trial Design

4Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Intralesional Triamcinolone 40 mg/mLExperimental Treatment1 Intervention
Each active hidradenitis suppurativa lesion will be injected with up to 1 mL of intralesional triamcinolone 40 mg/mL in up to 3 anatomic areas. The maximum treatment volume is 3 mL.
Group II: Intralesional Triamcinolone 20 mg/mLExperimental Treatment1 Intervention
Each active hidradenitis suppurativa lesion will be injected with up to 1 mL of intralesional triamcinolone 20 mg/mL in up to 3 anatomic areas. The maximum treatment volume is 3 mL.
Group III: Intralesional Triamcinolone 10 mg/mLActive Control1 Intervention
Each active hidradenitis suppurativa lesion will be injected with up to 1 mL of intralesional triamcinolone 10 mg/mL in up to 3 anatomic areas. The maximum treatment volume is 3 mL.
Group IV: Sodium Chloride 0.9%Placebo Group1 Intervention
Each active hidradenitis suppurativa lesion will be injected with up to 1 mL of sodium chloride 0.9% in up to 3 anatomic areas. The maximum treatment volume is 3 mL.

Find a Location

Who is running the clinical trial?

Montefiore Medical CenterLead Sponsor
441 Previous Clinical Trials
582,185 Total Patients Enrolled
4 Trials studying Hidradenitis Suppurativa
821 Patients Enrolled for Hidradenitis Suppurativa
Steven R Cohen, MD, MPHPrincipal InvestigatorAlbert Einstein College of Medicine Montefiore Medical Center
3 Previous Clinical Trials
432 Total Patients Enrolled
2 Trials studying Hidradenitis Suppurativa
402 Patients Enrolled for Hidradenitis Suppurativa

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Optimizing Intralesional Triamcinolone Dosing for Hidradenitis Suppurativa
2022. "Optimizing Intralesional Triamcinolone Dosing for Hidradenitis Suppurativa". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04582669.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top